Further comprehensive analyses revealed one gene, RAN (RAN, member RAS oncogene family), as the top candidate because this gene was highly expressed in GBM and its activity was robustly associated with drug resistance and poor prognosis in GBM. Here, RAN is linked to glioblastoma.